Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK042 and Ofatumumab in Multiple Sclerosis
NCT07546110Phase 1Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
Phase 1, open-label, single-arm trial of NK042 in multiple sclerosis (MS), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Incidence of Adverse Events and Serious Adverse Events at 48 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
NK042
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07546110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07546110.